MX2020007315A - Cristal. - Google Patents
Cristal.Info
- Publication number
- MX2020007315A MX2020007315A MX2020007315A MX2020007315A MX2020007315A MX 2020007315 A MX2020007315 A MX 2020007315A MX 2020007315 A MX2020007315 A MX 2020007315A MX 2020007315 A MX2020007315 A MX 2020007315A MX 2020007315 A MX2020007315 A MX 2020007315A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- compound
- radiation
- ray powder
- spectrum obtained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Steroid Compounds (AREA)
Abstract
Un objeto principal de la presente invención consiste en proporcionar un nuevo cristal de ácido 2-{4-[N-(5,6-difenilpirazin -2-il)-N-isopropilamino]butiloxi}acético (de ahora en más en la presente, mencionado como "compuesto B"). Un cristal de la forma I de compuesto B, que muestra picos en ángulos de difracción (2?) de 6,4°, 8,1°, 9,5°, 10,9°, 13,2°, 15,7°, 17,0°, 19,5°, 20,3°, 21,0° y 22,8° en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka(?=1,54 Å). Un cristal de la forma II de compuesto B, que muestra picos en ángulos de difracción (2?) de 9,6°, 11,4°, 11,7°, 16,3°, 17,5°, 18,5°, 18,7°, 19,9°, 20,1°, 21,0° y 24,6° en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka (?=1,54 Å).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017187296 | 2017-09-28 | ||
| PCT/JP2018/035828 WO2019065792A1 (ja) | 2017-09-28 | 2018-09-27 | 結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007315A true MX2020007315A (es) | 2020-08-20 |
Family
ID=65902864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007315A MX2020007315A (es) | 2017-09-28 | 2018-09-27 | Cristal. |
| MX2023004668A MX2023004668A (es) | 2017-09-28 | 2020-07-13 | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004668A MX2023004668A (es) | 2017-09-28 | 2020-07-13 | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10906879B2 (es) |
| EP (2) | EP3689854A4 (es) |
| JP (3) | JP7160043B2 (es) |
| KR (2) | KR102778758B1 (es) |
| CN (2) | CN111263754A (es) |
| AR (1) | AR112842A1 (es) |
| AU (2) | AU2018338856B2 (es) |
| BR (1) | BR112020005428A2 (es) |
| CA (2) | CA3076877C (es) |
| CO (1) | CO2020003424A2 (es) |
| IL (2) | IL317489A (es) |
| MX (2) | MX2020007315A (es) |
| MY (1) | MY202100A (es) |
| PH (1) | PH12020550149A1 (es) |
| SG (1) | SG11202002443QA (es) |
| TW (2) | TWI834536B (es) |
| UA (1) | UA126928C2 (es) |
| WO (1) | WO2019065792A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007315A (es) * | 2017-09-28 | 2020-08-20 | Nippon Shinyaku Co Ltd | Cristal. |
| WO2021023271A1 (zh) * | 2019-08-06 | 2021-02-11 | 南京明德新药研发有限公司 | 作为前列环素受体激动剂的化合物的晶型及其制备方法 |
| PH12022550380A1 (en) * | 2019-08-19 | 2023-03-13 | Nippon Shinyaku Co Ltd | Salt |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI316055B (es) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| EP2246336B1 (en) | 2008-02-28 | 2020-07-01 | Nippon Shinyaku Co., Ltd. | Fibrosis inhibitor |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| SI2289518T1 (sl) | 2008-06-23 | 2017-02-28 | Nippon Shinyaku Co., Ltd. | Terapevtsko sredstvo za vnetno črevesno bolezen |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| HRP20151443T1 (hr) | 2008-06-23 | 2016-01-29 | Nippon Shinyaku Co., Ltd. | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala |
| US8575175B2 (en) | 2008-07-23 | 2013-11-05 | Toray Industries, Inc. | Therapeutic agent for chronic renal failure |
| SG176915A1 (en) | 2009-06-26 | 2012-01-30 | Nippon Shinyaku Co Ltd | Crystals |
| CN106279047B (zh) * | 2015-05-13 | 2019-05-03 | 普济生物科技（台州）有限公司 | 一种前列环素受体激动剂的制备方法 |
| WO2017042828A2 (en) * | 2015-09-10 | 2017-03-16 | Megafine Pharma (P) Ltd. | Process for the preparation of selexipag and intermediates thereof |
| WO2017060827A1 (en) * | 2015-10-07 | 2017-04-13 | Lupin Limited | An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts |
| CA3029960A1 (en) * | 2016-07-05 | 2018-01-11 | Maithri Drugs Private Limited | Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof |
| CN106957269A (zh) * | 2016-12-21 | 2017-07-18 | 南京艾德凯腾生物医药有限责任公司 | 一种成人肺动脉高压治疗药物赛乐西帕的制备方法 |
| CN107365275B (zh) * | 2017-06-14 | 2020-07-03 | 杭州华东医药集团新药研究院有限公司 | 高纯度的赛乐西帕 |
| MX2020007315A (es) | 2017-09-28 | 2020-08-20 | Nippon Shinyaku Co Ltd | Cristal. |
-
2018
- 2018-09-27 MX MX2020007315A patent/MX2020007315A/es unknown
- 2018-09-27 TW TW112113059A patent/TWI834536B/zh active
- 2018-09-27 KR KR1020247009414A patent/KR102778758B1/ko active Active
- 2018-09-27 CN CN201880063158.XA patent/CN111263754A/zh active Pending
- 2018-09-27 AU AU2018338856A patent/AU2018338856B2/en active Active
- 2018-09-27 EP EP18860498.7A patent/EP3689854A4/en not_active Withdrawn
- 2018-09-27 JP JP2019545594A patent/JP7160043B2/ja active Active
- 2018-09-27 KR KR1020207008812A patent/KR102675320B1/ko active Active
- 2018-09-27 TW TW107134006A patent/TWI801421B/zh active
- 2018-09-27 SG SG11202002443QA patent/SG11202002443QA/en unknown
- 2018-09-27 MY MYPI2020001527A patent/MY202100A/en unknown
- 2018-09-27 CN CN202311466995.6A patent/CN117510418A/zh active Pending
- 2018-09-27 EP EP24159703.8A patent/EP4371617A3/en active Pending
- 2018-09-27 BR BR112020005428-3A patent/BR112020005428A2/pt unknown
- 2018-09-27 AR ARP180102776A patent/AR112842A1/es active IP Right Grant
- 2018-09-27 IL IL317489A patent/IL317489A/en unknown
- 2018-09-27 WO PCT/JP2018/035828 patent/WO2019065792A1/ja not_active Ceased
- 2018-09-27 US US16/650,390 patent/US10906879B2/en active Active
- 2018-09-27 CA CA3076877A patent/CA3076877C/en active Active
- 2018-09-27 IL IL273430A patent/IL273430B2/en unknown
- 2018-09-27 UA UAA202002567A patent/UA126928C2/uk unknown
- 2018-09-27 CA CA3296591A patent/CA3296591A1/en active Pending
-
2020
- 2020-03-24 CO CONC2020/0003424A patent/CO2020003424A2/es unknown
- 2020-03-26 PH PH12020550149A patent/PH12020550149A1/en unknown
- 2020-07-13 MX MX2023004668A patent/MX2023004668A/es unknown
- 2020-12-28 US US17/134,796 patent/US11655218B2/en active Active
-
2022
- 2022-09-27 JP JP2022154085A patent/JP7485738B2/ja active Active
-
2023
- 2023-04-12 US US18/133,666 patent/US12152009B2/en active Active
- 2023-11-29 AU AU2023274142A patent/AU2023274142B2/en active Active
-
2024
- 2024-02-21 JP JP2024024462A patent/JP7688744B2/ja active Active
- 2024-10-17 US US18/918,427 patent/US20250034098A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6430432A2 (es) | Cristales | |
| MX2015018048A (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PY1432622A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| CA2875877C (en) | Syk inhibitors | |
| EA201690127A1 (ru) | Состав на основе ингибиторов syk | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201792471A1 (ru) | Бигетероарильные соединения и их применения | |
| AR096582A1 (es) | Procesos de fabricación y formas cristalinas de un inhibidor de mdm2 | |
| JO3472B1 (ar) | مركبات ديهايدروبنزوفوران مفيدة في علاج السكري والسمنة | |
| MX2015014688A (es) | Tiazoles y usos de los mismos. | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| MX2023004668A (es) | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда | |
| MX390763B (es) | Compuestos de tetraciclina | |
| WO2015017378A3 (en) | Novel copper-cysteamine and methods of use | |
| NZ718576A (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| HK1212978A1 (zh) | 芥子酸的新型衍生物 | |
| UA113988C2 (xx) | Спосіб стабілізації бета-напівгідрату штукатурного гіпсу | |
| EA201200823A1 (ru) | Гетероциклические производные сульфонамидов |